Today: 9 June 2026
JB Hi-Fi (ASX:JBH) share price jumps 8% after record half-year sales and dividend hike — what to watch next
17 February 2026
2 mins read

JB Hi-Fi (ASX:JBH) share price jumps 8% after record half-year sales and dividend hike — what to watch next

Sydney, Feb 17, 2026, 16:59 AEDT — Market shut its doors for the day

  • JB Hi-Fi jumped roughly 8% by the close, after releasing its HY26 results and bumping up the interim dividend.
  • Retailer bumped up first-half sales and profit, and also increased its target for dividend payout ratio.
  • Attention is now on how January sales shaped up, along with upcoming dividend dates set for late February.

JB Hi-Fi jumped 8.1% Tuesday, finishing the day at A$89.10. That move easily beat the S&P/ASX 200, which added just 0.24%.

This development is grabbing attention as traders lean on earnings season to gauge one thing: are Australians keeping up their appetite for big-ticket purchases, or is the pullback finally here. JB Hi-Fi is right at the heart of it.

Dividends play a major role here. Whenever the payout rises, traders often shift their view—suddenly, the stock looks less like a typical retailer and, for a day or so, more like an income play.

JB Hi-Fi Limited posted a 7.3% jump in first-half sales, reaching A$6.10 billion, while net profit after tax rose 7.1% to A$305.8 million. The retailer declared a fully franked interim dividend of 210 cents per share, and raised its dividend payout ratio target to 70%-80% of NPAT, up from 65%. “We are pleased to report record sales and strong earnings for HY26,” CEO Nick Wells said. Contentful Assets

JB Hi-Fi, best known for consumer electronics and appliances, operates The Good Guys chain as well. Beyond that, it has stores in New Zealand and also controls the smaller e&s appliance brand.

JB Hi-Fi’s Australian sales climbed 6.3% to A$4.12 billion, with like-for-like sales up 5% after adjusting for new stores. Online revenue jumped 11.2% to A$759 million, making up 18.4% of total sales. Gross margin edged up 11 basis points to 21.95%—that’s 0.01 percentage point per basis point. The January figures pointed to slower momentum: JB Hi-Fi Australia posted a 4% rise, The Good Guys added 2.7%, while e&s slipped 4.6%.

Next up for debate: that January slowdown. It’s the stretch where, if promotions ramp up and margins take a hit, the stock could start to look pricey in a hurry.

Atlas Funds Management’s chief investment officer Hugh Dive pointed to the larger dividend as a key factor behind the buyer interest that followed JB Hi-Fi’s earlier share swings. “In this tighter environment with higher interest rates, JB Hi-Fi is well positioned to keep taking share,” Dive told Livewire Markets. He also flagged upcoming peer results as potential mood-setters for the rest of reporting season. Livewire Markets

There’s a caveat to the bullish scenario. Morningstar’s Johannes Faul isn’t on board for a breakout, writing, “We expect JB Hi-Fi’s sales growth to moderate,” and flagging the risk of shrinking margins if retailers are forced into deeper discounting, especially with Amazon and omnichannel competitors circling. Faul left his fair value at A$57—well below where the stock’s trading—and described the shares as “significantly overvalued.” Morningstar

Next session, the focus turns to whether momentum holds after that 8% pop, and if any fresh broker notes shake things up post-earnings. Another signal: does the market stick with dividend-heavy names, or does that trade unwind just as fast?

Dividend-watchers have their eyes on next week’s calendar: ex-dividend for the stock lands Feb. 26, with a record date following on Feb. 27. Payment hits March 13.

Stock Market Today

  • Proxy Adviser Supports Nanoco Group's Plan to Delist from LSE
    June 9, 2026, 9:17 AM EDT. Nanoco Group PLC, a nanotechnology firm, announced that independent proxy adviser Glass Lewis has recommended shareholders approve the company's resolution to delist from the London Stock Exchange (LSE). The move signals a significant shift for Nanoco, potentially changing its trading and regulatory environment. Shareholder approval for such a resolution typically permits a company to withdraw its shares from public exchange trading, often to pursue private ownership or alternative funding routes. This development follows Nanoco's strategic review and may impact investor access and share liquidity. The recommendation by Glass Lewis adds weight to the proposal ahead of the upcoming shareholder vote.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Tesco share price nudges toward 52-week high after UK retail sales jump — what to watch next
Next Story

Tesco share price nudges toward 52-week high after UK retail sales jump — what to watch next

Go toTop